BioVentureHub quarterly updateBy Jamie Smith - 27 Aug 2020
I hope you’ve had a relaxing and enjoyable summer. The BioVentureHub team is back in business and energised after the holidays. We’re looking forward to making the most of the challenges and opportunities that come our way throughout the rest of the year.
Before the summer break, we were very happy to announce a new, exciting collaboration with global medtech company, Mölnlycke. This collaboration further expands our unique collaboration environment, and offers SMEs and research groups invaluable access to Mölnlycke’s medtech expertise and know-how − free of charge.
The Mölnycke collaboration follows a similar collaboration between the BioVentureHub and IBM Sweden announced earlier this year. Both collaborations align with and underpin our firm belief that we need to think differently when we are designing healthcare solutions for the future.
As stated in the Swedish government’s national strategy for life science, we need to build new structures for cross-sector collaboration and convergence. We’re working to make that a reality in the BioVentureHub, and we’re very pleased that large, global companies like Mölnlycke, IBM and AstraZeneca share our ambition and are providing their expertise, experience and insights to fuel growth in the life science sector.
There is no getting away from the fact that we have found it challenging over the past months not being able to interact with current and potential BioVentureHub companies and stakeholders as we would normally do.
Having said that, I am so proud of my team who have stepped up and shown even greater levels of resilience, flexibility and creativity to ensure our business and operations are continued with minimal disruption.
I’m also really proud of the BioVentureHub companies who continue to invest and believe in the future. Despite the Corona pandemic, BioVentureHub companies have continued to grow their business and expand their teams. Since the start of the year, 27 new people have joined companies in the BioVentureHub, a number of whom are international recruitments.
During Q2, Alzinova, a Swedish biopharmaceutical company developing disease-modifying treatments against Alzheimer’s Disease, joined the BioVentureHub.
There are currently 28 companies and 1 academic group co-locating with us at the AstraZeneca Gothenburg site.
We are expecting more exciting companies to join us during Q3, exposing AstraZeneca to more science and technologies; and adding to the 4D (drugs, devices, diagnostics, digital solutions) life science environment we are catalyzing.
Also during Q2…
Magnus was elected as a Board Member of Global Compact Network Sweden, which aims to inspire and help Swedish companies in their work with corporate social responsibility and sustainability.
Amanda Lindenmeyer Asadi and Malin Stenbom completed their master thesis in Entrepreneurship and Business Design: ”Development of KPIs for an Innovation Initiative between Big Pharma and SMEs. A case study of AstraZeneca’s BioVentureHub”
The Innovator published an interview article with Magnus Björsne about the BioVentureHub and cross-sector convergence (article behind paywall).
Business Sweden has selected the BioVentureHub to be part of a Swedish government talent attraction program aiming to identify and attract international companies and expertise to Sweden. The BioVenturehub will focus on companies working in cutting-edge research areas of interest to AstraZeneca.
Here are eight Q2 success stories from BioVentureHub companies:
Antaros Medical’s proprietary method Imiomics (based on imaging studies) was used to help develop new insights in an Uppsala University and AstraZeneca collaboration on tissue-specific insulin resistance in diabetes type 2 using multi-omics.
Amferia was selected as “one to watch” in Nature’s inaugural Spinoff Prize, for the most exciting science-based companies to have emerged from academic labs in the past three years.
Athera Biotechnologies announced that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure.
Corline’s drug candidate, Renaparin®, demonstrated a good safety profile in first patient study.
Immunicum received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer for the treatment of metastatic Renal Cell Carcinoma (mRCC).
Immunicum also announced publication of phase I/II clinical trial results of Ilixadencel in Gastrointestinal Stromal Tumors (GIST) in Cancer Immunology, Immunotherapy
I-Tech announced that Norwegian paint-manufacturer, Jotun, has commercialized two new marine paint products containing I-Tech’s antifouling active agent Selektope®
NanoSIMS and AstraZeneca collaboration project - Sub-Cellular Mass Spectrometry Imaging and Absolute Quantitative Analysis across Organelles – was accepted for publication in ACS Nano.
Before you go…
Again, thank you so much for your continued support and encouragement. It is sincerely appreciated.
For more information about the BioVentureHub, please see:
Workplace (AstraZeneca employees only)
Take care and stay healthy!
CEO, AstraZeneca BioVentureHub